Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Orphanet Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol CDKN1B contributors: mct - updated : 13-07-2016
HGNC name cyclin-dependent kinase inhibitor 1B (p27, Kip1)
HGNC id 1785
Corresponding disease
MEN4 multiple endocrine neoplasia, type IV
Location 12p13.1      Physical location : 12.870.301 - 12.875.305
Synonym name cyclin-dependent kinase inhibitor p27
Synonym symbol(s) CDKN4, CDKN5, KIP1, P27, P27KIP1, MEN1B, MEN4
TYPE functioning gene
STRUCTURE 5.00 kb     3 Exon(s)
10 Kb 5' upstream gene genomic sequence study
MAPPING cloned Y linked N status confirmed
Map pter - D12S352 - D12S341 - D12S77 - ETV6 /D12S89 - D12S98 - D12S391 - D12S358 - CDKN1B - GPR19 - D12S1581 - D12S1580 - D12S269 - D12S310 - qter
Authors Cavé (95),Montpetit (99)
TRANSCRIPTS type messenger
identificationnb exonstypebpproduct
ProteinkDaAAspecific expressionYearPubmed
3 - 2413 - 198 - 2001 11115398
Type ubiquitous
   expressed in (based on citations)
SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
Digestiveesophagus   highly
 mouth   moderately
Hearing/Equilibriumearinnercochlea highly
Lymphoid/Immunespleen   moderately
 thymus   highly
Nervousbrain   highly
 nerve   highly
Reproductivefemale systemuteruscervix moderately
Respiratoryrespiratory tracttrachea  highly
SystemCellPubmedSpeciesStageRna symbol
 epithelial cell
cell lineage
cell lines
cell cycle     cell cycle, G1
life cycle quiescence
  • a CDK inhibitory domain
  • a proline-rich domain
  • an acidic repeat region
  • a conserved C terminal domain, with the presence of Threonine 198 fundamental for the regulation of CDKN1B functions and stability
    interspecies homolog to murine Cdkn1b (87.76 pc)
    homolog to rattus Cdkn1b (87.24 pc)
  • CDK inhibitor family
  • CATEGORY enzyme , regulatory
    SUBCELLULAR LOCALIZATION     intracellular
    basic FUNCTION
  • critical terminal effector of signal transduction pathways that control cell differentiation
  • essential regulator responsible for the blockade of clonal expression of anergic T cells in vitro
  • mediating TGFB inhibitor of cyclin-E CDK2, cyclin-D CDK4 complexes induced G1 arrest
  • mediating cell cycle regulation by AFX-like forkhead transcription factors
  • contributing to oligodendrocyte differentiation by regulating transcription of the MBP gene
  • functions as a distinct inhibitor for neural progenitor cells proliferation under homeostatic as well as ischemic conditions
  • mainly regulated by proteasomal degradation and its downregulation is often correlated with poor prognosis in several types of human cancers
  • potentially a critical regulator of the CD8 T-cell homeostasis at all phases of the T-cell response to an acute viral infection
  • role for CDKN1B as a tumor susceptibility gene for multiple endocrine tumors
  • MITF and CDKN1B are the key molecular switches that control the transition between melanoma-initiating cells and their differentiated progeny
  • required to maintain proliferative quiescence in the adult cochlea and pituitary
  • CDKN1B and CDKN1C cooperate to maintain hematopoietic stem cell quiescence through interactions with HSPA8
  • CDKN1B and CDKN1C control neuronal output for distinct cortical layers by regulating different stages of precursor proliferation
  • role for CDKN1B during cytokinesis via the regulation of CIT activity
  • CDKN1B inhibits F3 expression at the transcriptional level
  • CELLULAR PROCESS cell cycle
    nucleotide, repair
  • regulator of cell cycle
  • involved in G1 phase arrest and in the cellular response after DNA damage in cell cycle exit in megacaryocyte
    signaling signal transduction
  • activation of the SKP2-CDKN1B pathway in response to mitogenic stimulation of vascular smooth muscle cells and during neointima formation is mediated at least in part by NR4A3
  • a component
    small molecule
  • interaction with PDPK1 (PDPK1 plays an important role in cell proliferation and cell cycle progression by controlling the expression of both cyclin D1 and CDKN1B
  • functional link between STAT1 and CDKN1B, which act in coordination to suppress the oncogenic properties of activated RAS
  • interaction with CFL1 (cofilin expression and its regulation of CDKN1B expression is important for the control of G(1) phase progression)
  • interacts with MCM7, a DNA replication licensing factor, to inhibit initiation of DNA replication
  • a novel JAK2 substrate (JAK2 can directly bind and phosphorylate CDKN1B)
  • a novel target of HIPK2
  • WWP1 decreases CDKN1B protein levels and CDKN1B may play a key regulatory role in WWP1-mediated cellular senescence
  • HSPA8 interacts with both CDKN1C and CDKN1B and the subcellular localization of HSPA8 was critical to maintain HSC (hematopoietic stem cell) cycle kinetics
  • cellular function of CDKN1B as a transcriptional regulator in association with RBL2/E2F4 complexes that could be relevant for tumorigenesis
  • KAT2B induces CDKN1B degradation via proteasome
  • is involved in GJA1-induced neuronal translocation and morphological transformation in the subventricular (SVZ)/intermediate zone (IZ)
  • important role of TADA3-dependent control of CDKN1B levels in promoting cell cycle progression
  • YWHAE regulates cardiogenesis and growth of the compact ventricular myocardium by modulating the cardiomyocyte cell cycle via both CCNE1 and CDKN1B
  • receptor-specific function for NOTCH2 in mediating vascular smooth muscle cell growth arrest through CDKN1B
  • inverse expression pattern of CDKN1B and F3, but also a direct regulatory link between the two proteins
  • EXOC3 regulates cytoplasmic translocation of CDKN1B through CDKN1B phosphorylation at Thr157, thereby promoting CDKN1B degradation in the cytoplasm via interaction with COPS5 and SIAH1 and suppressing cell cycle progression
  • SMAD2 overexpression inhibits the proliferation of junctional epithelium (JE) cells by down-regulating MYC and up-regulating CDKN2B and CDKN1B, which resulted in an increase in RB1, leading to cell-cycle arrest
  • STMN1 is a relevant CDKN1B binding partner (cooperates with CDKN1B to control the early phase of G1 to S phase transition and this function may be of particular relevance in the context of tumor progression)
  • UBE2L3 specifically protects CDKN1B from degradation
  • MAST1 influences likely nervous system development by affecting neuronal differentiation through CDKN1B
  • critical role of PUM1 mediated translational control, particularly the PUM1-CDKN1B axis, in prostate cancer cell growth and tumorigenesis
  • cell & other
    activated by E2F1 (E2F1 activates transcription of two members of the CDKN1 family CDKN1B and CDKN1C) (Ma 2010)
    inhibited by COP9 signalosome negatively regulating cell cycle at the G1 phase by promoting denylation of CUL1
    repressed by mitogens that repress CDKN1B gene transcription in multiple systems and by multiple mechanisms
    Phosphorylated by HIPK2 (at serine 10, an event that accounts for 80p100 of the total CDKN1B phosphorylation and plays a crucial role in the stability of the protein)
    JAK2, that directly links cytokine receptor signaling to cell cycle control
    Other regulating-mediated degradation of CDKN1B,mediated by SKP2
    bound and degraded by UCHL1 via the interaction and nuclear translocation of UCHL1 with COPS5
    transactivated by BRCA1
    phosphorylated by RPS6KA1 (promoting its cytoplasmic localization)
    during the cell cycle to be under the control of the tumor suppressor tuberin
    calpain is a critical modulator for regulation of CDKN1B in cells of the osteoblast lineage
    corresponding disease(s) MEN4
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    with CCND3 in agressive B cell lymphoma
    tumoral     --low  
    in the development and progression of oral squamous cell carcinoma and in thyroid, colon, breast, prostate and superficial bladder carcinoma
    tumoral   deletion    
    deleted in leukemia and other cancers with poor prognosis (pancreas adenocarcinoma, esophageal squamous cell carcinoma), degraded by proteasomes in gliomas
    tumoral     --low  
    (when inhibited by AKT1) in aggressive breast cancer
    tumoral germinal mutation      
    in multiple endocrine neoplasia syndrome
    constitutional     --low  
    in both acute and end-stage heart failure
  • to advanced prostate carcinoma
  • to to the development of multiple endocrine tumors
  • to pituitary hyperplasia and tumorigenesis
  • to breast cancer
  • to Systemic lupus erythematosus (SLE)
  • Variant & Polymorphism other
  • genotype VV strongly associated with advanced prostate carcinoma
  • frequencies of CT genotype and T allele of CDKN1B were found to be higher in breast cancer patients than in controls
  • multiple independent SNPs increasing the risk of SLE
  • Candidate gene
    Therapy target
    modulation of CDKN1B could bolster vaccine-induced T-cell memory and protective immunity
    cardiovascularaquiredheart failure
    manipulation of CDKN1B protein levels could yield therapeutic benefits in the treatment of heart failure
    PUM1-CDKN1B regulatory axis may represent potential target for therapeutics development